02511.HK
HighTide Therapeutics Inc
HKSE · Healthcare · Biotechnology · CN
HKD 3.10
−0.32%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +45.7%
- EBIT
- +45.8%
- EPS
- +16.9%
- Free cash flow
- +34.8%
- Operating cash flow
- +33.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +50.5%
- EBIT
- +49.7%
- Net income
- +35.8%
- EPS
- +39.3%
- Free cash flow
- +44.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026